Brokerages Set Repligen Co. (NASDAQ:RGEN) Target Price at $178.64

Repligen Co. (NASDAQ:RGEN) has been assigned a consensus rating of “Moderate Buy” from the fourteen brokerages that are covering the company, MarketBeat.com reports. Six analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $178.64.

Several equities research analysts recently commented on the stock. Royal Bank of Canada lifted their price target on shares of Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research note on Friday, February 21st. JPMorgan Chase & Co. lifted their target price on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Evercore ISI started coverage on Repligen in a research report on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 target price for the company. StockNews.com lowered Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 21st. Finally, Canaccord Genuity Group increased their price objective on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a report on Friday, February 21st.

Repligen Stock Down 2.7 %

Shares of NASDAQ RGEN opened at $133.41 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen has a 1 year low of $113.50 and a 1 year high of $184.98. The company has a market capitalization of $7.49 billion, a price-to-earnings ratio of -261.59, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. The business has a 50-day moving average of $154.21 and a two-hundred day moving average of $148.19.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. On average, analysts forecast that Repligen will post 1.72 earnings per share for the current fiscal year.

Insider Activity at Repligen

In other Repligen news, Director Margaret Pax bought 250 shares of the company’s stock in a transaction on Monday, March 17th. The shares were bought at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the transaction, the director now owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.20% of the stock is currently owned by insiders.

Institutional Trading of Repligen

A number of institutional investors have recently modified their holdings of the business. Signaturefd LLC grew its stake in shares of Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 124 shares during the period. Sava Infond d.o.o. acquired a new position in shares of Repligen during the 4th quarter worth $29,000. Raiffeisen Bank International AG purchased a new position in Repligen during the 4th quarter valued at about $29,000. Resources Management Corp CT ADV acquired a new stake in shares of Repligen in the third quarter valued at approximately $37,000. Finally, Quarry LP raised its position in shares of Repligen by 796.7% during the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 239 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.